BridgeBio (BBIO) Bank of America 2025 Healthcare Conference summary

Strategic approach and operating model

• Focus on maximizing patient impact and sustainable value creation through a decentralized, efficiency-driven operating model, enabling multiple late-stage pipeline opportunities.

• Portfolio strategy emphasizes broad R&D with a transition to late-stage assets, targeting large and underserved markets.

ATTR-CM launch and commercial performance

• Early launch of acoramidis (Attruby) exceeded expectations, with $37 million in first full quarter revenue and strong uptake across patient segments.

• Clinical data shows rapid onset and significant outcome improvements, supporting strong physician and patient buy-in.

• Market opportunity estimated at $15–$20 billion peak, with ongoing growth and increasing community-based prescriber adoption.

• Net revenue per patient benefited from favorable gross-to-net and lower-than-expected use of free drug programs, expected to normalize over time.

Market dynamics and growth levers

• ATTR-CM market is expanding rapidly, with significant room for growth as diagnosis and awareness increase.

• Differentiation through clinical data, ease of access, and high-touch patient support programs are key competitive advantages.

• Ongoing focus on frontline, treatment-naive patients to drive long-term value.